Sung Tae Yoon is the Chairman at Huons Global Co, Ltd., and additionally holds position as the Chief Executive Officer at Huonslab Co., Ltd., S. Korea.

He is also the former President of KPBMA (Korea Pharmaceutical and Bio-Pharma Manufacturers Association) and has been appreciated, nominated and awarded for his dedication to the Korean pharmaceuticals industry numerous times.

He is a widely acknowledged and distinguished entrepreneur who has documented multiple success stories in, both organic and inorganic growth of Huons group throughout the last decades.

He took over the company in 1997 from his father, late Mr. Myeong Yong Yoon, the former chairman and founder of Kwang Myung Pharmaceuticals, which is the origin of Huons group, today.
Since then, the successful implementations of M&As, strategic investment into the R&D and cGMP manufacturing facilities have been observed.

In 2018, he established Huonslab Co., Ltd., and has been extensively and consistently investing into the Biologics R&D, and human hyaluronidase based Sub-Q delivery platform, HyDIFFUZE™.

Huons group has been ranked as the 10th-largest bio, pharma and healthcare group with an impressive 19y CAGR of 19%, last year.

Driven by his profound knowledge on medicines and manufacturing of the drug products along with the insights into the pharma industry, he made seminal contributions to the Korean society and industry with such an iconic entrepreneurial performance and speed.

Additionally, in regards to his academic background, he majored in Industrial Engineering at Han Yang University, under graduated and graduated with MSc., having a solid understanding and background of drug manufacturing and quality management system.

Huons global reported 758.4 billion won ($600.00 million) in consolidated sales and 114.8 billion won ($90 million) in operating profit in 2023, which are 14 percent and 33 percent up from the previous year 2022, respectively.

He is envisioned to achieve the group's consolidated sales to 1 trillion won by 2025 with more than 30 percent of the revenue to be generated from overseas.

With the anticipated future upside in Bio R&D and HyDIFFUZETM™, he and Huons group are boldly marching up to 3 trillion won sales within the next 5 years, consistently and persistently.